ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive: Consistently, Takahashi et al. observed that the dose-adjusted imatinib Ctrough was higher in patients with the AA or CA genotype for ABCG2 c.421C>A with respect to the CC carriers (dominant model) in a cohort of 67 Japanese CML patients [28].